Yu et al. (2022) reported a novel polymeric PROTAC 13 (POLY-PROTAC) nanoplatform for the tumor-targeted degradation of the bromodomain and extra-terminal (BET) protein, BRD4 [41]. The gene discussed is BRD4; the disease is neoplasm.